Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1)
Jingbo Xiao(National Center for Advancing Translational Sciences), Juan Marugán(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Noel Southall(National Institutes of Health), Irina U. Agoulnik(University of South Florida), Marc Ferrer(National Institute of Biomedical Innovation, Health and Nutrition), Xin Hu(Discovery Institute), Zaohua Huang(Florida International University), Alexander I. Agoulnik(Florida International University), Catherine Z. Chen(National Institutes of Health)
Unknown
May 8, 2013
Cited by 4
Related Papers
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Rethinking dog domestication by integrating genetics, archeology, and biogeography
|Proceedings of the National Academy of Sciences|2012|534
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
A transgenic insertion upstream of Sox9 is associated with dominant XX sex reversal in the mouse
|Nature Genetics|2000|351